Imagine discovering that a simple genetic test could prevent your child from suffering a heart attack in their 30s. Sounds like a no-brainer, right? But here's where it gets controversial: while screening kids for high cholesterol genes could save lives, it’s currently too expensive to implement widely. So, should we prioritize early detection despite the costs, or focus on more affordable strategies? Let’s dive in.
In the United States, about 1 in every 250 people is born with a genetic variant called familial hypercholesterolemia (FH), which causes dangerously high cholesterol levels from birth. Left untreated, these individuals face a significantly higher risk of heart attacks or strokes as early as their 30s or 40s. The shocking part? Only 1 in 10 people with FH—roughly 1.5 million Americans—even know they have it. Early intervention could change this, but how?
A groundbreaking study by researchers at Columbia and Harvard universities explored the costs and benefits of screening children and young adults for FH. Their findings, published in JAMA, reveal that while such screening could prevent countless premature heart attacks and strokes, the current price tag makes it impractical. And this is the part most people miss: the study suggests that universal cholesterol screening, combined with lifestyle changes for all high-risk individuals—not just those with FH genes—could make the process cost-effective.
Here’s the catch: One in five adolescents shows abnormalities in routine lipid screenings, yet fewer than 20% of children receive the recommended cholesterol tests between ages 9 and 11. Why? The upfront costs of genetic testing for FH are high, especially when only a small fraction of the population carries the gene. As Andrew Moran, a senior author of the study, explains, “Early recognition and management of high cholesterol, even in childhood, can prevent or delay heart attacks, strokes, and possibly dementia later in life.”
The researchers modeled a two-stage screening strategy: first, measuring cholesterol levels (LDL-C) in children at age 10 or 18, followed by genetic testing for FH in those with high readings. Surprisingly, they found that screening in young adulthood (around age 18) was the most cost-effective approach—but only if it led to intensive cholesterol management for all high-risk individuals, regardless of genetic test results.
Now, for the truly controversial question: Could newborn genetic screening be the game-changer we need? A recent JAMA Cardiology study demonstrated that FH screening using blood spots collected for newborn screening is feasible on a large scale. The Columbia and Harvard teams are now collaborating with those researchers to explore this approach further. An added benefit? Newborn screening could identify at-risk family members who might also have undiagnosed FH—a factor current models don’t even account for.
So, where do we go from here? Moran admits, “We haven’t landed on the best way to screen early for FH yet, but our modeling is helping us identify the most promising approaches for real-world clinical trials.”
What do you think? Is it worth investing in costly genetic screening to save lives, or should we focus on more affordable, universal strategies? Let us know in the comments—this debate is far from over.
